BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 37474760)

  • 21. Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells.
    Scotlandi K; Avnet S; Benini S; Manara MC; Serra M; Cerisano V; Perdichizzi S; Lollini PL; De Giovanni C; Landuzzi L; Picci P
    Int J Cancer; 2002 Sep; 101(1):11-6. PubMed ID: 12209582
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EWS-FLI1-mediated suppression of the RAS-antagonist Sprouty 1 (SPRY1) confers aggressiveness to Ewing sarcoma.
    Cidre-Aranaz F; Grünewald TG; Surdez D; García-García L; Carlos Lázaro J; Kirchner T; González-González L; Sastre A; García-Miguel P; López-Pérez SE; Monzón S; Delattre O; Alonso J
    Oncogene; 2017 Feb; 36(6):766-776. PubMed ID: 27375017
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protein phosphatase 1 regulatory subunit 1A in ewing sarcoma tumorigenesis and metastasis.
    Luo W; Xu C; Ayello J; Dela Cruz F; Rosenblum JM; Lessnick SL; Cairo MS
    Oncogene; 2018 Feb; 37(6):798-809. PubMed ID: 29059150
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A steric blocker of translation elongation inhibits IGF-1R expression and cell transformation.
    Lecosnier S; Cordier C; Simon P; François JC; Saison-Behmoaras TE
    FASEB J; 2011 Jul; 25(7):2201-10. PubMed ID: 21402719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.
    Kurmasheva RT; Dudkin L; Billups C; Debelenko LV; Morton CL; Houghton PJ
    Cancer Res; 2009 Oct; 69(19):7662-71. PubMed ID: 19789339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. OVA66 increases cell growth, invasion and survival via regulation of IGF-1R-MAPK signaling in human cancer cells.
    Rao W; Li H; Song F; Zhang R; Yin Q; Wang Y; Xi Y; Ge H
    Carcinogenesis; 2014 Jul; 35(7):1573-81. PubMed ID: 24667688
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulation of Hippo-YAP signaling by insulin-like growth factor-1 receptor in the tumorigenesis of diffuse large B-cell lymphoma.
    Zhou X; Chen N; Xu H; Zhou X; Wang J; Fang X; Zhang Y; Li Y; Yang J; Wang X
    J Hematol Oncol; 2020 Jun; 13(1):77. PubMed ID: 32546241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EWS-FLI1 regulates and cooperates with core regulatory circuitry in Ewing sarcoma.
    Shi X; Zheng Y; Jiang L; Zhou B; Yang W; Li L; Ding L; Huang M; Gery S; Lin DC; Koeffler HP
    Nucleic Acids Res; 2020 Nov; 48(20):11434-11451. PubMed ID: 33080033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. C/EBPβ-1 promotes transformation and chemoresistance in Ewing sarcoma cells.
    Gardiner JD; Abegglen LM; Huang X; Carter BE; Schackmann EA; Stucki M; Paxton CN; Lor Randall R; Amatruda JF; Putnam AR; Kovar H; Lessnick SL; Schiffman JD
    Oncotarget; 2017 Apr; 8(16):26013-26026. PubMed ID: 28148901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of G Protein-Coupled Receptor Kinase 2 Promotes Unbiased Downregulation of IGF1 Receptor and Restrains Malignant Cell Growth.
    Crudden C; Shibano T; Song D; Dragomir MP; Cismas S; Serly J; Nedelcu D; Fuentes-Mattei E; Tica A; Calin GA; Girnita A; Girnita L
    Cancer Res; 2021 Jan; 81(2):501-514. PubMed ID: 33158816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth.
    Sankar S; Theisen ER; Bearss J; Mulvihill T; Hoffman LM; Sorna V; Beckerle MC; Sharma S; Lessnick SL
    Clin Cancer Res; 2014 Sep; 20(17):4584-97. PubMed ID: 24963049
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma.
    Sankar S; Bell R; Stephens B; Zhuo R; Sharma S; Bearss DJ; Lessnick SL
    Oncogene; 2013 Oct; 32(42):5089-100. PubMed ID: 23178492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting the IGF1R/PI3K/AKT Pathway Sensitizes Ewing Sarcoma to BET Bromodomain Inhibitors.
    Loganathan SN; Tang N; Holler AE; Wang N; Wang J
    Mol Cancer Ther; 2019 May; 18(5):929-936. PubMed ID: 30926641
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EWS/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing's sarcoma.
    Kinsey M; Smith R; Iyer AK; McCabe ER; Lessnick SL
    Cancer Res; 2009 Dec; 69(23):9047-55. PubMed ID: 19920188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modeling the initiation of Ewing sarcoma tumorigenesis in differentiating human embryonic stem cells.
    Gordon DJ; Motwani M; Pellman D
    Oncogene; 2016 Jun; 35(24):3092-102. PubMed ID: 26455317
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma.
    Lamhamedi-Cherradi SE; Menegaz BA; Ramamoorthy V; Vishwamitra D; Wang Y; Maywald RL; Buford AS; Fokt I; Skora S; Wang J; Naing A; Lazar AJ; Rohren EM; Daw NC; Subbiah V; Benjamin RS; Ratan R; Priebe W; Mikos AG; Amin HM; Ludwig JA
    J Natl Cancer Inst; 2016 Dec; 108(12):. PubMed ID: 27576731
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ewing sarcoma: The clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway.
    van Maldegem AM; Bovée JV; Peterse EF; Hogendoorn PC; Gelderblom H
    Eur J Cancer; 2016 Jan; 53():171-80. PubMed ID: 26765686
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TAE226, a dual inhibitor of focal adhesion kinase and insulin-like growth factor-I receptor, is effective for Ewing sarcoma.
    Moritake H; Saito Y; Sawa D; Sameshima N; Yamada A; Kinoshita M; Kamimura S; Konomoto T; Nunoi H
    Cancer Med; 2019 Dec; 8(18):7809-7821. PubMed ID: 31692287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis.
    Showpnil IA; Miller KR; Taslim C; Pishas KI; Lessnick SL; Theisen ER
    J Vis Exp; 2020 Jun; (160):. PubMed ID: 32658189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma.
    Goss KL; Gordon DJ
    Oncotarget; 2016 Sep; 7(39):63003-63019. PubMed ID: 27557498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.